(PharmaNewsWire.Com, September 28, 2021 ) By product, the shunts segment held the largest share of the market in 2017
By product, the cerebrospinal fluid (CSF) management market is segmented into shunts and external drainage systems. In 2017, the shunts segment accounted for the largest share of the global market. The large share of this segment can be primarily attributed to growing number of shunting procedures performed worldwide as well as the increasing number of revision shunt surgeries owing to shunt malfunction and infection.
By end user, the pediatric segment accounted for the largest share of the market in 2017
On the basis of end user, the cerebrospinal fluid (CSF) management market is segmented into pediatric, adult, and geriatric end users. In 2017, the pediatric segment held the largest share of the global market. The large share of this segment can be primarily attributed to high prevalence of congenital hydrocephalus along with the rising number of shunting procedures in the pediatric population.
North America to dominate the market in 2017
In 2017, North America held the largest share of the cerebrospinal fluid (CSF) management market, followed by Europe. Factors such as the rising prevalence of hydrocephalus, increasing funding for hydrocephalus research in the US, and the launch of Hydrocephalus Canada are contributing to the dominant share of this region.
The high prevalence of hydrocephalus and the subsequent increase in the number of shunting procedures and the growing geriatric population are major factors driving the market growth. The growing healthcare market in developing economies is also expected to provide growth opportunities for players in the market. On the other hand, the dearth of trained professionals and complications related to CSF shunts may challenge market growth to a certain extent.
Hydrocephalus affects a large number of people worldwide. According to the Hydrocephalus Association, more than 1 million people in the US are reportedly suffering from hydrocephalus. Similarly, 700,000 older Americans are living with normal pressure hydrocephalus (NPH). According to CURE Hydrocephalus estimates, over 400,000 newborns suffer from infant hydrocephalus around the globe each year. Moreover, congenital hydrocephalus affects a huge number of infants worldwide.
The World Economic Forum estimates that these emerging economies will account for around one-third of the global healthcare expenditure by 2020. Moreover, more than half of the world’s population resides in India and China, owing to which these countries are home to a large patient pool.
Hydrocephalus affects a large number of people in developing countries. According to CURE Hydrocephalus, of the total number of children born with hydrocephalus globally, 79% are born in the developing world. It was estimated that there were over 6,000 new cases of hydrocephalus reported per year in East Africa. According to the International Federation for Spina Bifida and Hydrocephalus, over 375,000 new cases of infant hydrocephalus are reported in sub-Saharan Africa each year.
The key players in the global cerebrospinal fluid (CSF) management market are Medtronic (Ireland), Integra (US), B. Braun (Germany), DePuy Synthes (US), Spiegelberg GmbH & Co. KG (Germany), SOPHYSA (France), Natus Medical Incorporated (US), Dispomedica GmbH (Germany), Delta Surgical Limited (UK), Argi Grup (Turkey), Moller Medical GmbH (Germany), G. SURGIWEAR LTD. (India), and Wellong Instruments Co., Ltd. (Taiwan).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
